Head-to-head · free
Moderna vs Regeneron Pharmaceuticals, Inc.
MRNA vs REGN — return on capital, cash generation, margins and balance sheet side by side.
MRNA
0 / 7
measures where MRNA leads
REGN
7 / 7
measures where REGN leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MRNA · FY2025 | REGN · FY2025 |
|---|---|---|
| Revenue | $1.9B | $14.3B |
| Net income | (2.8B) | $4.5B |
| Revenue growth (yearly, multi-year) | -43.0% | -2.8% |
| Free cash flow | (2.1B) | — |
| Free cash flow margin | -106.2% | — |
| Net cash / (debt) | — | — |
| ROIC | — | 9.3% |
| Return on equity | -28.9% | 14.9% |
| Gross margin | 54.8% | 85.4% |
| Operating margin | -159.9% | 25.8% |
| Net debt / EBITDA | 0.70x | -0.27x |
Figures are as reported by each company; latest fiscal year shown.
Where Moderna's cash went (FY2025)
- Capital spending
- $192.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Regeneron Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free